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About Professor Pete Coffey
Prof. Coffey received a B.Sc. in Experimental Psychology
from the University of Sussex in 1986 and then went on to
earn his D.Phil in Experimental Psychology from the Univer-
sity of Oxford in 1995. On completing his doctoral work,
Prof. Coffey joined the faculty at Oxford University in the
Department of Experimental Psychology. In 1989 he was
awarded a Robert and Joan Case Royal Society Research Fel-
lowship, and at the same time moved to the University of
Shefﬁeld, subsequently becoming a lecturer and senior lec-
turer before moving to London in 2004. Prof. Coffey is now
Chair of Cellular Therapies and Visual Sciences at the Insti-
tute of Ophthalmology at University College London. He is
also Research Head of the Department of Ocular Biology and
Therapeutics.
Among his many achievements, he has done seminal
work on retinal transplantation, he is the principle author and
co-author of two landmark papers demonstrating the use of
human cells to halt visual deterioration in models of age-
related macular degeneration, he developed the ﬁrst transplant
strategy to treat inherited macular degeneration, and he has
developed a cell-based therapy for age-related macular degen-
eration. He also helped launch, and is now the Director of,
the London Project to Cure Blindness.
‘‘People Have Been Investigating Stem Cells to
Repopulate the Cells of the Cornea...for the Last
10 Years.’’
Even before stem cells began to make their mark on research
and therapeutics, Prof. Coffey was working on cell therapies
to replace dying cells in the eye. He was studying techniques
based on the use of adult cells that had been either taken
from biopsies or that had been donated, which were then
immortalized and scaled up. But, explains Prof Coffey, ‘‘with
the emergence of several breakthroughs in stem cell science,
it became clear very quickly that this new technology was
where the ﬁeld should be headed. Stem cell technology prom-
ised the new ability to take a fresh cell and use this as the
raw material to actually produce other new, fresh cells.’’
Research in Prof. Coffey’s lab now focuses on stem cell
therapeutics, along three main lines. ‘‘In my laboratory, we are
interested in using stem cells to understand and treat diseases
of the eyes, and in particular, disease affecting the back of the
eye, or the neural retina, as well as the cells and vasculature
that support the neural retina. To do this, we are differentiating
human ESCs into the types of cells that have been lost due to
disease.’’ Interestingly, the use of stem cells in ophthalmology
is not new. ‘‘For the last 10 years people have been looking at
stem cells to repopulate the cells of the cornea, which may
have been damaged due to acid or alkali burns, or because of
genetic disease. So the front of the eye has already been
served quite well by the use of stem cells. But now, new thera-
pies are beginning to emerge for the back of the eye.’’
‘‘We are also investigating the possibility of using bioengi-
neered scaffolds so that we can put the cells back into patients
in a much more structured way; instead of just injecting the
cells, we can actually form patches of cells which are properly
differentiated and have all the characteristics of the cells
which have died and which we would like to replace. A third
line of investigation in my lab is the newer technology of iPS
cells. That is, being able to take a somatic cell, typically some-
thing like a skin cell, and turn it into a stem cell, using the
knowledge we’ve gained from our studies of hESCs.’’
‘‘We Are Aiming to Begin Trials
[for Macular Degeneration] in 2011.’’
‘‘I think that the ﬁrst use of stem cells in the back of the eye
will be the use of stem cells to repopulate the retinal pigment
epithelial cells, which support the neural retina, and are inti-
mately involved with the blood supply at the back of the eye.
One disease that shows promise to be treated with this type of
stem cell therapy is age related macular degeneration, which
results in a loss of vision in the central visual ﬁled due to
damage to the retina. This is an enormous clinical problem,
and there aren’t any good therapies available at the moment
for the dry form of the disease. We are beginning to under-
take early stage trials, phase I and phase II, using stem cell to
treat macular degeneration. We’re differentiating hESCs into
retinal pigmented epithelia cells, and then putting these back
into patients with age related macular degeneration where
cells have died. Right now, we are in the throws of going
through the regulatory processes required to undertake these
trials, as well as producing these cells to clinical grade stand-
ards, and we aim to begin these trials in 2011.’’
‘‘Another major disease in terms of the size of the clinical
need is diabetic retinopathy, which is probably the biggest
ophthalmological problem in the working population. Here,
we need to ﬁnd a way of replacing the vasculature that is
affected in this disease. I also think that there is the possibil-
ity of eventually replacing damaged photoreceptor cells, to
help conditions such as retinal pigmentosa.’’ There are also
researchers looking at the possibility of using stem cells in
glaucoma, a disease in which there is loss of retinal ganglion
cells, leading to damage of the optic nerve and loss of vision.
‘‘Although there are some people looking at replacing these
cells, the major problem is that these cells travel a very long
distance to connect to the brain, and in addition, there are a
number of structures to which they must connect. So I think
that glaucoma treatment will likely be more about trying to
protect these cells and keep them from dying rather than
replacing them.’’
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Disease Processes and to Identify New Therapeutic
Targets are Immense.’’
‘‘I think one of the most important developments in stem cell
science is, and will continue to be, our ability to properly dif-
ferentiate the cells. We need to be able to get the speciﬁc eye
cells that we need, such as the retinal pigment epithelial cells
or photoreceptors, to enable at least the possibility of consid-
ering these as a source of therapeutic value in terms of cell
replacement. This requires a lot of knowledge surrounding the
developmental biology of the eye, in combination with the
biology of stem cells.’’
‘‘This is why there is real excitement now about the new
technology of iPS cells. While this technology is still in its
infancy, and probably at the moment still isn’t positioned to
be used as a cell replacement therapy in its own right
(although I do believe that will happen, and probably very
soon), they provide immense possibilities to study develop-
ment and disease processes. They provide us with the phenom-
enal possibility of actually taking samples from speciﬁc
patients with a disease and then producing in the Petri dish the
very cells which are affected by the disease; these can then be
used to study disease pathogenesis and develop bioassays. We
can then probe the very cells which are being diseased in those
patients, and look at potential therapeutic targets. I think this
will really take off and evolve quite quickly, and will be very
beneﬁcial for the ﬁeld of ophthalmology, where there are sev-
eral known genetic defects which lead to disease.’’
‘‘At the moment, hESCs deﬁnitely have more potential to
treat many people. Because in this case, potentially, ‘one will
ﬁt all’. We’ll know this very soon, in 2011 when we begin
our macular degeneration trials, if that’s the case. So I think
in terms of therapeutic value, the hESCs still have huge
potential and probably will be the major type of stem cell
going into the clinic in the beginning. I think there is still an
issue about whether iPS cells can really be seen as a technol-
ogy for therapeutics. It would be very expensive to produce a
cell from a speciﬁc patient and then go through all of the
quality assessment and scaling up that would be needed to go
into the clinic. I think that there are still a number of signiﬁ-
cant issues that need to be addressed before we are able to
consider using iPS cells as therapeutics. However, as I said,
the possibility of using them to understand disease processes
and identify new therapeutic targets is immense.’’
Proactive Legislation ‘‘is Necessary to Ensure the
Safety of Patients.’’
‘‘One of the biggest obstacles that needs to be overcome in
order to use stem cells therapeutically is to ensure that the
cells are safe. And they need to be safe in two different ways.
First, we must ensure that the cells do not possess the ability
to form teratomas, and second, we must ensure that the
immunological responses that could be triggered by these
cells are not going to be deleterious. While the possibility of
teratomas, of course, needs to be excluded completely, in
terms of the immunological response, it may be possible to
manage this by some type of therapeutic intervention, for
example, by immunosupression. But these problems are be-
ginning to be addressed; we now have studies identifying
what things deﬁnitely need to be targeted to make sure there
is no ongoing proliferation in the cells which could lead to
teratomas, and it is also now clear that some of these cells
don’t express a major immunogenicity component, so immune
suppression may not be necessary.’’
‘‘The other big obstacle to using stem cells therapeutically
is the scaling up of the cells, to obtain the large number of
cells that you need for each patient, and how to ensure that
they are still produced to clinical grade standards and still
meet quality control levels. To undertake early trials in phase
I and phase II, only a limited number of cells are needed,
because only a few patients, say 10 or so, will be enrolled in
the trials. But there are hundreds of thousands of patients in
the clinical population in general, and so many more cells
would have to be produced to meet the needs of these patients
if these cells were to be used clinically.’’
Dr. Coffey believes that the legislation regarding stem
cells in the UK will continue to be helpful in getting stem
cell therapies into the clinic. ‘‘In the UK, the legislation sur-
rounding the use of stem cell is very positive, and proactive I
think. Stem cell research and therapeutics is highly regulated,
and there are a number of organizations that are involved in
the process from the very onset, including the Human Fertility
and Embryology Authority, the Human Tissue Authority, the
Medicines and Healthcare Products Regulatory Agency, as
well as other ethics committees such as the Gene Therapy
Advisory Commission in Europe. So although there is legisla-
tion, I would say that it is very proactive, and while it is quite
a process to go through, it is helping us to ultimately reach
the clinic with these treatments, and I also feel is it necessary
to ensure the safety of patients.’’
‘‘There can be some problems involved in collaborating
with researchers in countries that do not have the same
types of legislation. For instance, until recently in the US no
federal funds could be used for human embryonic research,
unless the research used a few speciﬁcally approved cell
lines, although that has changed with the new administra-
tion. And some states have on their own taken a more pro-
active stance to stem cell legislation. For instance California
took a stance early on to be very proactive in the use of
hESCs, and made a very bold statement which the tax
payers themselves are paying for. This lead to the establish-
ment of the California Institute for Regenerative Medicine
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However, there are some countries where stem cells research
is without doubt very difﬁcult, particularly for labs trying to
get funding for hESC research, where investigators still have
to spend a lot of time just battling for basic funding to do
the research.’’
The Pathway to Clinical
Dr. Coffey believes that over the next 10 years the most im-
portant aspect of stem cell research will be the pathway to
clinic. ‘‘If this technology is really going to step up to the
mark, then we really do need to fully understand all the issues
in this pathway to clinic, which includes safety and toxicity
issues, as well as regulatory issues - we need to know what
exactly the regulatory authorities will expect. And again, if
this is to be seen as a viable therapeutic, we need to address
the issues of scaling up the process, to be able to meet the
clinical needs throughout the world.’’
‘‘As we get closer to using stem cell as therapies in clinics,
we do hear worries from the general public – and many are
misconceptions. I think one is the misconception about the biol-
ogy of stem cells. There is this idea that no matter what the dis-
ease is, stem cells will cure it for you. There has to be the
understanding that stem cells are not ‘magical’ cells; they still
function within the bounds of biology, so we can’t just expect
them to magically cure people, that’s not the way it works. I
think another major public misconception is that actually getting
the stem cells is the problem, but it’s not. We do have the stem
cells, the problems are around how we turn these stem cells
into the cells we need to beneﬁt that clinical population.’’
‘‘I think we have to be honest with the public in terms of
the number of applications that there will be initially – there
will be only a few – possibly age related macular degenera-
tion, and maybe some aspects of heart disease and diabetes,
for instance. But the type of press releases that are often seen
around, for example, Alzheimer disease or Parkinson’s dis-
ease, may be premature. I think that neural replacement treat-
ments will be a lot more complex because they involve very
complex neural systems, in which the cells will have to inter-
act properly with each other.’’
‘‘Another misconception in the public is that we are going
to have to go back continually for the blastocysts – the eggs
from which we derive the hESCs, but that’s not necessary. To
give one example, we’re trying now to scale up stem cells for
use in macular degeneration, a clinical population that
includes millions of people globally, but we do not need to
keep going back to fertilized eggs. We are using only one
hESC line, and that should be able to scale up to produce
enough cells for that whole clinical population’’.
‘‘Scientists could better educate the public by discussions,
or have meetings where everyone can discuss the whole
agenda around stem cells, such as what they are and how
they are used. Just recently I did a presentation at the Well-
come Collection Gallery in London, and next week I will be
going up to the north of England to visit a local macular
degeneration society, to discuss issues around stem cells. I
think that scientists themselves have to engage with the public
in whatever forums are available.’’
‘‘I am also Director of the London Project to Cure Blind-
ness. Back in April 2007, following a major donation from an
American philanthropist, we set up this Project speciﬁcally to
help take a cell therapy for age related macular degeneration
from the lab into the clinic. The whole goal was to start to
scale up the whole process from the beginning, and to bring
on board from the very start of the project not just basic sci-
entists but clinical scientists and engineers, and people
involved in the whole process of getting treatments into the
clinic. Usually, research like this is done in serial; that is, you
do a bit of basic research, then you do a bit preclinical work,
then you look at what may be the clinical issues. Doing this
serially takes a lot of time and at each stage there is also the
problem of ﬁnding funding. But this substantial donation
allowed a very cross-disciplinary research group to work to-
gether from the very start, to try to power very quickly the
translation from the basic science to the clinic, and I think
that is a valuable research model.’’
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